Microfluidic Organ Chip model of human blood-brain barrier that recapitulates in vivo barrier functions offers new preclinical tool for development of brain-targeting therapeutics
Like airport security barriers that either clear authorized or block unauthorized travelers and their luggage from accessing central operation areas, the blood-brain barrier (BBB) tightly controls the transport of essential nutrients and energy metabolites into the brain and staves off unwanted substances circulating in the blood stream. Importantly, its highly organized structure of thin blood vessels and supporting cells is also the major obstacle preventing life-saving drugs from reaching the brain in order to effectively treat cancer, neurodegeneration, and other diseases of the central nervous system. In a number of brain diseases, the BBB can also locally break down, causing neurotoxic substances, blood cells, and pathogens to leak into the brain and wreak irreparable havoc.
To study the BBB and drug transport across it, researchers have mostly relied on animal models such as mice. However, the precise make-up and transport functions of BBBs in those models can significantly differ from those in human patients, which makes them unreliable for the prediction of drug delivery and therapeutic efficacies. Also, in vitro models attempting to recreate the human BBB using primary brain tissue-derived cells thus far have not been able to mimic the BBB’s physical barrier, transport functions, and drug and antibody shuttling activities closely enough to be useful as therapeutic development tools.
Now, a team led by Donald Ingber, M.D.,Ph.D. at Harvard’s Wyss Institute for Biologically Inspired Engineering has overcome these limitations by leveraging its microfluidic Organs-on-Chips (Organ Chips) technology in combination with a developmentally-inspired hypoxia-mimicking approach to differentiate human pluripotent stem (iPS) cells into brain microvascular endothelial cells (BMVECs). The resulting “hypoxia-enhanced BBB Chip” recapitulates cellular organization, tight barrier functions, and transport abilities of the human BBB; and it allows the transport of drugs and therapeutic antibodies in a way that more closely mimics transport across the BBB in vivo than existing in vitro systems. Their study is reported in Nature Communications.
“Our approach to modeling drug and antibody shuttling across the human BBB in vitro with such high and unprecedented fidelity presents a significant advance over existing capabilities in this enormously challenging research area,” said Ingber, who is the Wyss Institute’s Founding Director. “It addresses a critical need in drug development programs throughout the pharma and biotech world that we now aim to help overcome with a dedicated ‘Brain Targeting Program’ at the Wyss Institute using our unique talent and resources.” Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, as well as Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS).
The BBB consists of thin capillary blood vessels formed by BMVECs, multifunctional cells known as pericytes that wrap themselves around the outside of the vessels, and star-shaped astrocytes, which are non-neuronal brain cells that also contact blood vessels with foot-like processes. In the presence of pericytes and astrocytes, endothelial cells can generate the tightly sealed vessel wall barrier typical of the human BBB.
Ingber’s team first differentiated human iPS cells into brain endothelial cells in the culture dish using a method that had been previously developed by co-author Eric Shusta, Ph.D., Professor of Chemical and Biological Engineering at University of Wisconsin-Madison, but with the added power of bioinspiration. “Because in the embryo the BBB forms under low-oxygen conditions (hypoxia), we differentiated iPS cells for an extended time in an atmosphere with only 5% instead of the normal 20% oxygen concentration,” said co-first author Tae-Eun Park, Ph.D. “As a result, the iPS cells initiated a developmental program very similar to that in the embryo, producing BMVECs that exhibited higher functionality than BMVECs generated in normal oxygen conditions.” Park is a former Postdoctoral Fellow on Ingber’s team who is now an Assistant Professor at Ulsan National Institute of Science and Technology in the Republic of Korea.
Building on a previous human BBB model, the researchers next transferred the hypoxia-induced human BMVECs into one of two parallel channels of a microfluidic Organ Chip device that are divided by a porous membrane and continuously perfused with medium. The other channel was populated with a mixture of primary human brain pericytes and astrocytes. Following an additional day of hypoxia treatment, the human BBB Chip could be stably maintained for at least 14 days at normal oxygen concentrations, which is far longer than past in vitro human BBB models attempted in the past.
Under the shear stress of the fluids perfusing the BBB Chip, the BMVECs go on to form a blood vessel, and develop a dense interface with pericytes aligning with them on the other side of the porous membrane, as well as with astrocytes extending processes towards them through small openings in the membrane. “The distinct morphology of the engineered BBB is paralleled by the formation of a tighter barrier containing elevated numbers of selective transport and drug shuttle systems compared to control BBBs that we generated without hypoxia or fluid shear stress, or with endothelium derived from adult brain instead of iPS cells,” said Nur Mustafaoglu, Ph.D., a co-first author on the study and Postdoctoral Fellow working on Ingber’s team. “Moreover, we could emulate effects of treatment strategies in patients in the clinic. For example, we reversibly opened the BBB for a short time by increasing the concentration of a mannitol solute [osmolarity] to allow the passage of large drugs like the anti-cancer antibody Cetuximab.”
To provide additional proof that the hypoxia-enhanced human BBB Chip can be utilized as an effective tool for studying drug delivery to the brain, the team investigated a series of transport mechanisms that either prevent drugs from reaching their targets in the brain by pumping them back into the blood stream (efflux), or that, in contrast, allow the selective transport of nutrients and drugs across the BBB (transcytosis).
“When we specifically blocked the function of P-gp, a key endothelial efflux pump, we could substantially increase the transport of the anti-cancer drug doxorubicin from the vascular channel to the brain channel, very similarly to what has been observed in human patients,” said Park. “Thus, our in vitrosystem could be used to identify new approaches to reduce efflux and thus facilitate drug transport into the brain in the future.”
In other efforts, drug developers are trying to harness “receptor-mediated transcytosis” as a vehicle for shuttling drug-loaded nanoparticles, larger chemical and protein drugs, as well as therapeutic antibodies across the BBB. “The hypoxia-enhanced human BBB Chip recapitulates the function of critical transcytosis pathways, such as those used by the LRP-1 and transferrin receptors responsible for taking up vital lipoproteins and iron from circulating blood and releasing them into the brain on the other side of the BBB. By harnessing those receptors using different preclinical strategies, we can faithfully mimic the previously demonstrated shuttling of therapeutic antibodies that target transferrin receptors in vivo, while maintaining the BBB’s integrity in vitro,” said Mustafaoglu.
Based on these findings, the Wyss Institute has initiated a “Brain Targeting Program.” “Initially, the BBB Transport Program aims to discover new shuttle targets that are enriched on the BMVEC vascular surface, using novel transcriptomics, proteomics, and iPS cell approaches. In parallel, we are developing fully human antibody shuttles directed against known shuttle targets with enhanced brain-targeting capabilities,” said James Gorman, M.D., Ph.D., the Staff Lead on the Advanced Technology Team for the BBB Transport Program working with Ingber. “We aim to collaborate with multiple biopharmaceutical partners in a pre-competitive relationship to develop shuttles offering exceptional efficacy and engineering flexibility for incorporation into antibody and protein drugs, because this is so badly needed by patients and the whole field.”
The authors think that in addition to drug development studies, the hypoxia-enhanced human BBB Chip can also be used to model aspects of brain diseases that affect the BBB such as Alzheimer’s and Parkinson’s disease, and to advance personalized medicine approaches by using patient-derived iPS cells.
The Latest on: Brain-targeting therapeutics
via Google News
The Latest on: Brain-targeting therapeutics
- The challenge of delivering RNA-interference therapeutics to their target cellson October 16, 2019 at 8:56 am
“The conundrum of RNA therapeutics has always been delivery,” says Bo Rode Hansen, chief executive of Genevant Sciences, a company in Cambridge, Massachusetts, that focuses on delivery methods for ...
- Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood–brain barrier penetrationon June 4, 2019 at 2:10 am
Gold nanoparticles (AuNPs) displays the multifunctional characteristics in therapeutics, imaging ... it is therefore necessary to introduce novel tropism for brain targeting into these synthetic ...
- Global Intranasal Drug Delivery Industryon January 17, 2019 at 8:04 am
The report profiles 64 companies including many key and niche players such as: - Aegis Therapeutics LLC - AptarGroup ... for Sinusitis Intranasal Administration of ATX-LIPO for Brain Targeting - A ...
- Alzheimer’s disease: pathogenesis, diagnostics, and therapeuticson January 4, 2019 at 4:00 pm
From submission to first editorial decision. Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and ...
- Quantum Genomics’ brain-targeting blood pressure drug meets phase 2b endpointson November 12, 2018 at 8:24 am
Quantum Genomics’ blood pressure drug firibastat, an inhibitor that targets aminopeptidase A in the brain, met its primary endpoint in a phase 2b study—which the company says paves the way for a wider ...
- 36. Nanoparticle Functionalization for Brain Targeting Drug Delivery and Diagnosticon September 16, 2018 at 7:46 am
It summarizes the nanoparticles potential in therapeutics and molecular targeting to BBB, and also an approach of the nanoparticle-mediated drug transport across the BBB, where nanoparticles take ...
- Mayo Seeks Patent On Non-Invasive Drug Delivery For Brain Cancer, Alzheimer’son January 31, 2017 at 4:00 pm
They called their system “the least complicated, least expensive and most versatile method for delivering therapeutics to the brain ... which may be utilized for brain targeting of chemotherapy drugs.
- Stem cell gene therapy for fatal childhood disease ready for human trialon May 10, 2016 at 5:00 pm
This improves brain targeting and effectiveness. Professor Bobby Gaspar, Chief Scientific Officer of Orchard Therapeutics said: "Stem cell gene therapy has shown promising effects in several different ...
- Arizona company licenses CT inventor's Alzheimer's techon July 22, 2015 at 5:00 pm
Eric Knight of Farmington’s Remarkable Technologies said Phoenix’s NeuroEM Therapeutics has taken a no-fee research and development license for an apparatus he patented in May, designed to deliver ...
- Aptamers - the genesis of nanogenetics for neuro-ailmentson March 6, 2013 at 12:00 am
reveal their potential role at two levels: As therapeutic agents interrupting functions of over-expressed proteins underlying disease pathogenesis As active brain targeting ligands ... in the area of ...
via Bing News